Replies to post #222974 on Biotech Values

[biocqr]

CELG, BMY > UPDATED: Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

https://endpts.com/bristol-myers-inks-a-74b-deal-to-buy-out-celgene-expects-15b-a-year-from-late-stage-pipeline/

Bristol-Myers is counting on about $15 billion in near-term annual revenue from Celgene’s late-stage pipeline, turning to the drugs that Celgene has been buying up or partnering with companies like bluebird bio. That includes:

Two in immunology and inflammation, TYK2 and ozanimod; and
Four in hematology, luspatercept, liso-cel (JCAR017), bb2121 and fedratinib.

The CVR, worth up to $9 each, is based on FDA approval of all three of these drugs: “ozanimod (by December 31, 2020), liso-cel (JCAR017) (by December 31, 2020) and bb2121 (by March 31, 2021).”

The acquisition marks the combination of two of the world’s top-10 R&D operations. Celgene — which spent $6 billion on R&D in 2017 — built the company on Revlimid sales, and invested billions of that revenue in building its pipeline with a long string of deals.

[DewDiligence]

BMY acquires CELG for $74B in cash+stock + CVR:

https://finance.yahoo.com/news/bristol-myers-squibb-acquire-celgene-115800546.html

Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene.

… Based on the closing price of Bristol-Myers Squibb stock on January 2, 2019, the cash and stock consideration to be received by Celgene shareholders is valued at $102.43 per share. The cash and stock consideration represents an approximately…54 percent premium to Celgene shareholders based on the closing stock price of Celgene on January 2, 2019.

Each share also will receive one tradeable CVR, which will entitle its holder to receive a one-time potential payment of $9.00 in cash upon FDA approval of all three of ozanimod (by December 31, 2020), liso-cel (JCAR017) (by December 31, 2020) and bb2121 (by March 31, 2021), in each case for a specified indication.

…Bristol-Myers Squibb shareholders are expected to own approximately 69 percent of the company, and Celgene shareholders are expected to own approximately 31 percent.